+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Attenuated Mismatch Negativity in Attenuated Psychosis Syndrome Predicts Psychosis: Can Galantamine-Memantine Combination Prevent Psychosis?



Attenuated Mismatch Negativity in Attenuated Psychosis Syndrome Predicts Psychosis: Can Galantamine-Memantine Combination Prevent Psychosis?



Molecular Neuropsychiatry 4(2): 71-74



Although first proposed in 1987, early diagnosis and intervention of psychotic disorders has only recently become a priority in the field. The interest in clinical high risk (CHR) for psychosis skyrocketed after attenuated psychosis syndrome (APS) was added to the DSM-5. There is evidence that in individuals with APS, attenuated mismatch negativity (MMN: functioning of the auditory sensory memory system) is a robust biomarker that can predict transition to psychosis. The underlying pathophysiological mechanism of MMN is via the interaction of N-methyl-D-aspartate (NMDA) and alpha-7 nicotinic acetylcholine (α-7nACh) receptors. Galantamine is an acetylcholinesterase inhibitor and a positive allosteric modulator of the α-7nACh receptors. Memantine is an NMDA receptor antagonist. Memantine has been shown to enhance MMN in people with schizophrenia. Although no studies with galantamine have measured MMN, encenicline, an α-7 nicotinic partial agonist, increased MMN in people with schizophrenia. MMN has been suggested as a potential biomarker with the galantamine-memantine combination for the treatment of neuropsychiatric disorders. Hence, the galantamine-memantine combination may enhance MMN, thereby preventing CHR to psychosis. With no treatments available, randomized controlled trials are warranted with the galantamine-memantine combination to delay or prevent conversion to psychosis in individuals with CHR.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 065707175

Download citation: RISBibTeXText

PMID: 30397594


Related references

Public Stigma in China Associated With Schizophrenia, Depression, Attenuated Psychosis Syndrome, and Psychosis-Like Experiences. Psychiatric Services 67(7): 766-770, 2016

Can N‑acetylcysteine, varenicline, or the combination prevent psychosis by enhancing mismatch negativity?. Schizophrenia Research 206: 452-453, 2019

Emotional Experiences Predict the Conversion of Individuals with Attenuated Psychosis Syndrome to Psychosis: A 6-Month Follow up Study. Frontiers in Psychology 7: 818, 2016

Diagnostic and Prognostic Significance of DSM-5 Attenuated Psychosis Syndrome in Services for Individuals at Ultra High Risk for Psychosis. Schizophrenia Bulletin 44(2): 264-275, 2018

Declining transition rates to psychosis: the role of diagnostic spectra and symptom overlaps in individuals with attenuated psychosis syndrome. Schizophrenia Research 159(2-3): 292-298, 2014

Schizotypal personality disorder in individuals with the Attenuated Psychosis Syndrome: Frequent co-occurrence without an increased risk for conversion to threshold psychosis. Journal of Psychiatric Research 114: 88-92, 2019

Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis. Biological Psychiatry 71(2): 98, 2012

Mismatch Negativity reduction in the left cortical regions in first-episode psychosis and in individuals at ultra high-risk for psychosis. Schizophrenia Research 158(1-3): 58-63, 2014

Impaired mismatch negativity to frequency deviants in individuals at ultra-high risk for psychosis, and preliminary evidence for further impairment with transition to psychosis. Schizophrenia Research 191: 95, 2018

Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention. Neuropsychiatry 2(4): 345-353, 2012

Psychosis risk screening in youth: a validation study of three self-report measures of attenuated psychosis symptoms. Schizophrenia Research 141(1): 72-77, 2012

Learned irrelevance and associative learning is attenuated in individuals at risk for psychosis but not in asymptomatic first-degree relatives of schizophrenia patients: translational state markers of psychosis?. Schizophrenia Bulletin 37(5): 973-981, 2011

Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity. Journal of Geriatric Care and Research 5(2): 57-67, 2018

Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. European Child and Adolescent Psychiatry 25(10): 1091-1102, 2016

Reduced duration mismatch negativity in adolescents with psychotic symptoms: further evidence for mismatch negativity as a possible biomarker for vulnerability to psychosis. Bmc Psychiatry 13: 45, 2013